|Bid||7.36 x 0|
|Ask||7.59 x 0|
|Day's Range||7.09 - 7.59|
|52 Week Range||6.39 - 23.89|
|Beta (5Y Monthly)||-0.16|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 15, 2022 - Mar. 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.00|
VICTORIA, British Columbia & OSS, Netherlands, January 18, 2022--IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the relocation of its IPA Europe Oss laboratories to a new multi-tenant biotech Center of Excellence at the Pivot Park Campus in Oss, Netherlands.
VICTORIA, British Columbia, January 17, 2022--IMMUNOPRECISE ANTIBODIES LTD. ("IPA" or the "Company") (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that on January 13, 2022 its board of directors approved the grant of 15,000 stock options (the "Options") under its stock option plan to acquire up to an aggregate of 15,000 common shares in the capital of IPA ("Common Shares"). The Options were granted to a certain officer of IPA. Each Option is
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can...